SILO (SILO Pharma) GF Score: 42/100 (As of Sep. 11, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SILO SILO Pharma Inc SILO
42 GF Score
Price $2.10
GF Value $3.44
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SILO Pharma GF Score?

SILO Pharma SILO 42 GF Score is 42 as of Sep. 11, 2026, which is at its 10-year median of 42.00. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review.

SILO Pharma has the GF Score of 42, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 4/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes SILO Pharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

SILO Pharma  (NAS:SILO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

SILO Pharma GF Score Related Terms

SILO vs ELAB, GLMD, APVO: GF Score Comparison

For the Biotechnology subindustry, SILO Pharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SILO Pharma GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's GF Score distribution charts can be found below:

* The bar in red indicates where SILO Pharma's GF Score falls into.


SILO
42GF Score
SILO Pharma Inc SILO
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 42 mean?
SILO Pharma (SILO) has a GF Score of 42 as of Sep. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SILO Pharma and its competitors. This is near median its historical median of 42.00. Over the past decade, SILO Pharma's GF Score has ranged from 20.00 to 63.00.
Is SILO Pharma's GF Score too high?
SILO Pharma's current GF Score of 42 is near median its 10-year median of 42.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 63.00. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's GF Score compare to ELAB and GLMD?
SILO Pharma's GF Score of 42 can be compared against companies in the Biotechnology industry. Historically, SILO Pharma's own GF Score has ranged from 20.00 to 63.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SILO Pharma and its competitors. SILO Pharma's current GF Score is 42, which is near median its own 10-year median of 42.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current GF Score is 42, which is near median its 10-year median of 42.00. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For SILO Pharma (SILO), the current GF Score is 42 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SILO Pharma (SILO) Overvalued in 2026?

Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued. The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44. GuruFocus considers SILO Pharma to be Possible Value Trap.

Key valuation signals for SILO:

  • GF Score: 42 (near median its 10-year median of 42.00)
  • GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SILO Pharma Business Description

Address 677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score

Get the complete analysis for SILO

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$3.44
GF Value